<DOC>
	<DOCNO>NCT02512575</DOCNO>
	<brief_summary>This Phase I , first-in-human ( FIH ) , randomize , single-blind , placebo-controlled , single ascend dose sequential group study healthy male subject . The objective study safety , tolerability , pharmacokinetics effect glucose homeostasis ( pharmacodynamics ) AZD9567 , oral differentiate non-steroidal selective glucocorticoid receptor modulator ( SGRM ) . The study also assess safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) prednisolone 60 mg comparison high dos AZD9567 placebo .</brief_summary>
	<brief_title>A Single Ascending Dose Study To Assess The Safety , Tolerability , Pharmacokinetics And Pharmacodynamics Of AZD9567 .</brief_title>
	<detailed_description>This Phase I , first-in-human ( FIH ) , randomize , single-blind , placebo-controlled , single ascend dose sequential group study healthy male subject . The objective study safety , tolerability , pharmacokinetics effect glucose homeostasis ( pharmacodynamics ) AZD9567 . Additional exploratory variable ( Inflammation biomarkers , ECG model taste assessment ) also evaluate . The study also assess safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) prednisolone 60 mg comparison high dos AZD9567 placebo . The study conduct single study centre plan number subject 72 healthy male , age 18 55 year .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure . Healthy male subject age 18 55 year suitable vein cannulation repeat venipuncture . Have body mass index ( BMI ) 18 29.9 kg/m2 inclusive weigh least 50 kg 100 kg inclusive . Normal OGTT screening ( &lt; 7.8 mmol/L ) . Serum cortisol level within normal limit screen ( collect part clinical chemistry panel ) . Able understand , read speak German language . History clinically important disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . History active latent tuberculosis ( TB ) , risk acquire TB ( social worker prison staff country endemic rate TB , live patient know TB ) . History suggest abnormal immune function , judge investigator . Any contraindication treat prednisolone ( allergy ingredient , systemic fungal infection , certain type malaria , inflammation optic nerve , herpes infection eye , schedule live attenuate live vaccination take mifepristone ) . History severe affective disorder include depressive manicdepressive illness self first degree relative . History previous steroid psychosis Any clinically important illness , medical/surgical procedure , trauma within 4 week first administration IMP . Any latent chronic infection ( e.g. , recurrent sinusitis , genital ocular herpes , urinary tract infection ) risk infection ( surgery , trauma , significant infection ) , history skin abscess within 90 day prior first administration IMP . Any clinically important laboratory abnormality ( clinical chemistry , hematology , coagulation urinalysis result ) , judge investigator . In particular subject abnormal value alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gammaglutamyl transpeptidase ( GGT ) , creatinine , thyroidstimulating hormone ( TSH ) , fast glucose , International Normalised Ratio ( INR ) , haemoglobin ( Hb ) , white blood cell ( WBC ) , absolute neutrophil platelet count exclude . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) . Abnormal vital sign , 10 minute supine rest , define follow : Systolic BP ( SBP ) &lt; 90mmHg ≥ 140 mmHg , Diastolic BP ( DBP ) &lt; 50mmHg ≥ 90 mmHg , Pulse &lt; 45 &gt; 85 beat per minute ( bpm ) . Any clinically important abnormality rhythm , conduction morphology rest ECG clinically important abnormality 12lead ECG , consider investigator may interfere interpretation QTc interval change , include abnormal STTwave morphology , particularly protocol define primary lead leave ventricular hypertrophy . Prolonged QTcF &gt; 450 m family history long QT syndrome . PR ( PQ ) interval shorten &lt; 120 m ( PR &gt; 110 m &lt; 120 m acceptable evidence ventricular preexcitation ) . PR ( PQ ) interval prolongation ( &gt; 240 m ) intermittent second ( Wenckebach block asleep exclusive ) third degree AV block , AV dissociation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>AZD9567</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Phase 1</keyword>
	<keyword>placebo control</keyword>
	<keyword>single ascend dose</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>